Bristol-Myers Squibb Company
0R1F.L
London Stock Exchange54.60
USD
-0.75
- -
Bristol-Myers Squibb Company
0R1F.L
(London Stock Exchange)
Recent
price
54.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY; LSE: 0R1F) is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, and distributes innovative medicines for serious diseases in oncology, hematology, immunology, cardiovascular, and neuroscience; headquartered in Princeton, New Jersey, with roots tracing to the 1889 merger of Bristol-Myers and Squibb entities. The company offers a broad portfolio of marketed products including Eliquis (apixaban) for atrial fibrillation; Opdivo (nivolumab) and Yervoy (ipilimumab) for immuno-oncology indications; Revlimid (lenalidomide) and Pomalyst (pomalidomide) for multiple myeloma; Orencia (abatacept) for rheumatoid arthritis and other autoimmune conditions; Reblozyl (luspatercept) for anemia in myelodysplastic syndromes and beta thalassemia; CAR T-cell therapies Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) for certain blood cancers; Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy; Cobenfy (xanomeline and trospium) for schizophrenia; Krazati (adagrasib) for lung cancer; and legacy brands such as Abraxane, Idhifa, Inrebic, Nulojix, and Baraclude; with operations spanning the United States (71% of 2024 revenues), Europe, Asia, and other regions through research sites in New Jersey, California, Massachusetts, Belgium, Japan, India, and the United Kingdom. Recent developments include the 2025 acquisition of Orbital Therapeutics to bolster cell therapy capabilities; creation of a new immunology company with Bain Capital in July 2025; global strategic partnership with BioNTech in June 2025 for bispecific antibody BNT327 in solid tumors; completion of acquisitions of Karuna Therapeutics in March 2024 adding KarXT (now Cobenfy) for neuroscience, RayzeBio in February 2024 for radiopharmaceuticals, and Mirati Therapeutics in January 2024 enhancing oncology; a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing; and FDA approval of Cobenfy in September 2024 as the first novel schizophrenia treatment in 70 years.